Christine Marie Utter Sells 1,381 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,381 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total transaction of $106,267.95. Following the sale, the chief accounting officer directly owned 74,962 shares in the company, valued at approximately $5,768,325.90. The trade was a 1.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Christine Marie Utter also recently made the following trade(s):

• On Wednesday, January 7th, Christine Marie Utter sold 1,235 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.45, for a total transaction of $95,650.75.

PTC Therapeutics Stock Up 0.9%

Shares of PTC Therapeutics stock opened at $77.53 on Friday. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50. The company’s 50 day moving average is $76.61 and its 200 day moving average is $62.72. The company has a market cap of $6.22 billion, a price-to-earnings ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.39) EPS. Sell-side analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Analysts Set New Price Targets

PTCT has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price target on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Citigroup lifted their price target on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Finally, Barclays upped their price objective on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $77.27.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent quarterly results showed an upside surprise (EPS and revenue beat), supporting valuation and reducing near-term execution risk. MarketBeat PTCT Summary
• Positive Sentiment: At least one independent researcher upgraded PTC from Hold to Buy (Wall Street Zen), and several firms have raised price targets in November — a bullish offset to otherwise muted analyst sentiment. Wall Street Zen Upgrade
• Neutral Sentiment: Analysts as a group still carry a consensus “Hold” rating on PTCT, indicating limited immediate upside from broker consensus alone. Analyst Consensus
• Neutral Sentiment: The company reported a routine inducement grant of 300 RSUs for a new non-executive hire under Nasdaq rules — small dilution and not material to fundamentals. PR Newswire
• Negative Sentiment: A director executed a large sale totaling $916,200, a notable insider disposition that can weigh on sentiment. Director Sale
• Negative Sentiment: Broad insider selling reported in multiple SEC Form 4 filings (CEO, CFO, EVP, VP, CAO and others sold shares in early January). The scale and breadth of executive sales likely represent profit-taking or diversification and can create short-term downward pressure until offset by fresh operational news. Representative SEC filing: SEC Form 4
• Negative Sentiment: EVP Lee Scott Golden and other insiders sold modest-to-large blocks (multiple transactions disclosed), reinforcing the headline of concentrated insider exits. InsiderTrades Alert

Institutional Trading of PTC Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of PTCT. Empowered Funds LLC purchased a new position in shares of PTC Therapeutics during the 1st quarter valued at $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after acquiring an additional 18,504 shares during the period. Bayforest Capital Ltd bought a new stake in PTC Therapeutics during the first quarter valued at about $415,000. Intech Investment Management LLC lifted its position in shares of PTC Therapeutics by 62.8% in the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock valued at $2,003,000 after acquiring an additional 15,167 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of PTC Therapeutics by 6.1% in the first quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock worth $1,904,000 after acquiring an additional 2,140 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.